We have located links that may give you full text access.
Therapeutic effect of oligomeric proanthocyanidin in cuprizone-induced demyelination.
Experimental Physiology 2019 Februrary 28
NEW FINDINGS: What is the central question of this study? Oligomeric proanthocyanidin (OPC) has the capacity to alleviate abnormalities in neurological functioning. However, whether OPC can reduce the progression of demyelination or promote remyelination in demyelinating diseases remains unknown. What is the main finding and its importance? OPC can improved cuprizone (CPZ)-induced demyelination by inhibiting immune cell infiltration, reversing over-activated microglia, decreasing the inflammatory cytokines secreted by inflammatory cells and decreasing the production of MOG35-55 specific antibody in the brain.
ABSTRACT: Demyelinating diseases of the central nervous system (CNS), including multiple sclerosis (MS), neuromyelitis optica, acute disseminated encephalomylitis, are characterized by recurrent primary demyelination/remyelination and progressive neurodegeneration. In the present study, we investigate the therapeutic effect of oligomeric proanthocyanidin (OPC), the most effective component of grape seed extract, in cuprizone (CPZ)-fed C57BL/6 mice, a classic demyelination/remyelination model. Our results show that OPC attenuated abnormal behavior, reduced demyelination, and increased expression of myelin basic protein (MBP) and expression of O4+ oligodendrocytes in the corpus callosum. OPC also reduced the numbers of B cells and T cells, activated microglia in the corpus callosum, and inhibited secretion of inflammatory factors. Further, concentrations of myelin oligodendrocyte glycoprotein-specific antibodies were significantly reduced in serum and brain homogenates after OPC treatment. Together, these results demonstrate a potent therapeutic effect for OPC in CPZ-mediated demyelination and clearly highlight multiple effects of this natural product in attenuating myelin-specific autoantibodies and the inflammatory microenvironment in the brain. This article is protected by copyright. All rights reserved.
ABSTRACT: Demyelinating diseases of the central nervous system (CNS), including multiple sclerosis (MS), neuromyelitis optica, acute disseminated encephalomylitis, are characterized by recurrent primary demyelination/remyelination and progressive neurodegeneration. In the present study, we investigate the therapeutic effect of oligomeric proanthocyanidin (OPC), the most effective component of grape seed extract, in cuprizone (CPZ)-fed C57BL/6 mice, a classic demyelination/remyelination model. Our results show that OPC attenuated abnormal behavior, reduced demyelination, and increased expression of myelin basic protein (MBP) and expression of O4+ oligodendrocytes in the corpus callosum. OPC also reduced the numbers of B cells and T cells, activated microglia in the corpus callosum, and inhibited secretion of inflammatory factors. Further, concentrations of myelin oligodendrocyte glycoprotein-specific antibodies were significantly reduced in serum and brain homogenates after OPC treatment. Together, these results demonstrate a potent therapeutic effect for OPC in CPZ-mediated demyelination and clearly highlight multiple effects of this natural product in attenuating myelin-specific autoantibodies and the inflammatory microenvironment in the brain. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app